Please register **until 3rd of September 2020** at https://survey.zdv.uni-mainz.de/index.php/916321



Organisation Dr. Ann-Kathrin Herrmann Scientific Coordinator


Universitäres Centrum für Tumorerkrankungen Mainz (UCT Mainz) University Medical Center Mainz Langenbeckstr. 1 55131 Mainz

Phone: +49 (0) 6131 - 175487 Email: uct-science@uct-mainz.de

Sponsored by







The UCT Mainz presents

2nd Mini-Symposium in Translational Oncology (MiTraC) "Targeting Resistance in Cancer Immunotherapy"

10th of September 2020 | 1:00 - 6:00 pm Online Symposium

Unser Wissen für Ihre Gesundheit



uct Universitäres Centrum für Tumorerkrankungen MAINZ

The UCT Mainz presents

2nd Mini-Symposium in Translational Oncology (MiTraC) "Targeting Resistance in Cancer Immunotherapy"

Dear friends & colleagues,

we are happy to welcome you to the 2nd UCT Mainz Mini-Symposium in Translational Oncology (MiTraC) sponsored by Merck KGaA.

In this Mini-Symposium series we aim to address important areas of cancer research linked to translational oncology. Within this format, we have the opportunity to invite outstanding scientists to present novel findings, techniques and ideas. We also offer the possibility to talk to selected speakers working at the current edge of knowledge in cancer treatment and research.

The topic of this year's symposium is "Targeting Resistance in Cancer Immunotherapy", focussing on the prominent scientific core area of the UCT Mainz – Immuno-Oncology. The talks will cover major interests of research groups working at the UCT and our partnering institutions and clinics. To foster collaboration, we also want to invite you to talk to the speakers during the coffee break and wrap up new insights from the conference.

We wish you a pleasant time and an interesting symposium with lots of new insights and discoveries!

With best regards,

Thomas Kindler Head of the UCT Mainz Ann-Kathrin Herrmann Scientific Coordinator UCT Mainz

Program

12.30 Uhr Start Log in & Assembly of Participants

13.00 Uhr Welcome Thomas Kindler, UCT Mainz & Ralph Lindemann, Merck KGaA

Session 1: Immuno-Oncology & Resistance Chair: Nadine Hövelmeyer, Mainz

- 13.15 Uhr Immunogenicity in gastrointestinal cancers: now you see me, now you don 't Marco Gerlinger, London
- 13.55 Uhr Modelling resistance to antigen-specific T cell therapy of melanoma Maike Effern, Bonn
- 14.35 Uhr Novel immune resistance mechanisms in cancer Philipp Beckhove, Regensburg

15.15 Uhr Coffee Break & Speaker's Corner

Session 2: Combinational Onco-Immunotherapy & Prediction Chair: Borhane Guezguez, Mainz

15.45 Uhr	Targeting DNA Damage Response signaling to improve the anti- tumor efficacy of immune check- point inhibitors Astrid Zimmermann, Darmstadt & Marat Alimzhanov, Billerica
16.25 Uhr	Rational cancer and immune cell therapy combinations - a functional genomics approach Astrid Alflen, Amsterdam
17.05 Uhr	Tertiary lymphoid structures and B cells as predictors of response to immunotherapy Wolf H. Fridman, Paris
17.45 Uhr	Closing Remarks & Summary